Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk

Show full item record



Seidelmann , S B , Feofanova , E , Yu , B , Franceschini , N , Claggett , B , Kuokkanen , M , Puolijoki , H , Ebeling , T , Perola , M , Salomaa , V , Shah , A , Coresh , J , Selvin , E , MacRae , C A , Cheng , S , Boerwinkle , E & Solomon , S D 2018 , ' Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk ' , Journal of the American College of Cardiology , vol. 72 , no. 15 , pp. 1763-1773 .

Title: Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk
Author: Seidelmann, Sara B.; Feofanova, Elena; Yu, Bing; Franceschini, Nora; Claggett, Brian; Kuokkanen, Mikko; Puolijoki, Hannu; Ebeling, Tapani; Perola, Markus; Salomaa, Veikko; Shah, Amil; Coresh, Josef; Selvin, Elizabeth; MacRae, Calum A.; Cheng, Susan; Boerwinkle, Eric; Solomon, Scott D.
Contributor: University of Helsinki, Research Programs Unit
University of Helsinki, Research Programs Unit
Date: 2018-10-09
Language: eng
Number of pages: 11
Belongs to series: Journal of the American College of Cardiology
ISSN: 0735-1097
Abstract: BACKGROUND Loss-of-function mutations in the SGLT1 (sodium/glucose co-transporter-1) gene result in a rare glucose/galactose malabsorption disorder and neonatal death if untreated. In the general population, variants related to intestinal glucose absorption remain uncharacterized. OBJECTIVES The goat of this study was to identify functional SGLT1 gene variants and characterize their clinical consequences. METHODS Whole exome sequencing was performed in the ARIC (Atherosclerosis Risk in Communities) study participants enrolled from 4 U.S. communities. The association of functional, nonsynonymous substitutions in SGLT1 with 2-h oral glucose tolerance test results was determined. Variants related to impaired glucose tolerance were studied, and Mendelian randomization analysis of cardiometabotic outcomes was performed. RESULTS Among 5,687 European-American subjects (mean age 54 +/- 6 years; 47% mate), those who carried a haplotype of 3 missense mutations (frequency of 6.7%)-Asn51Ser, Ala411Thr, and His615Gln-had lower 2-h glucose and odds of impaired glucose tolerance than noncarriers (beta-coefficient: -8.0; 95% confidence interval [CI]: -12.7 to -3.3; OR: 0.71; 95% CI: 0.59 to 0.86, respectively). The association of the haplotype with oral glucose tolerance test results was consistent in a replication sample of 2,791 African-American subjects (beta = -16.3; 95% CI: -36.6 to 4.1; OR: 0.39; 95% CI: 0.17 to 0.91) and an external European-Finnish population sample of 6,784 subjects (beta = -3.2; 95% CI: -6.4 to 0.02; OR: 0.81; 95% CI: 0.68 to 0.98). Using a Mendelian randomization approach in the index cohort, the estimated 25-year effect of a reduction of 20 mg/dl in 2-h glucose via SGLT1 inhibition would be reduced prevalent obesity (OR: 0.43; 95% CI: 0.23 to 0.63), incident diabetes (hazard ratio [HR]: 0.58; 95% CI: 0.35 to 0.81), heart failure (HR: 0.53; 95% CI: 0.24 to 0.83), and death (HR: 0.66; 95% CI: 0.42 to 0.90). CONCLUSIONS Functionally damaging missense variants in SGLT1 protect from diet-induced hyperglycemia in multiple populations. Reduced intestinal glucose uptake may protect from long-term cardiometabolic outcomes, providing support for therapies that target SGLT1 function to prevent and treat metabolic conditions. (C) 2018 Published by Elsevier on behalf of the American College of Cardiology Foundation.
Subject: glucose tolerance
Mendelian randomization
3121 General medicine, internal medicine and other clinical medicine

Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0735109718369225_main.pdf 956.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record